INDIANAPOLIS, INDIANA - American pharmaceutical company, Eli Lilly and Co said on Wednesday interim trial data showed its experimental antibody treatment reduced the need for hospitalisation and emergency room visits for patients with moderate Covid-19.
Analysts expect antibody treatments could help some patients, as broad distribution of coronavirus vaccine candidates is expected to be lengthy. Of the total 302 patients treated with three different doses of LY-CoV555, five of them, or 1.7 per cent, had to be admitted to a hospital or visited a hospital emergency room, compared with 6 per cent, or 9 out of 150 on placebo, Lilly said.